查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750781

思觉失调症药物市场规模、份额、趋势分析报告（按药物类别、给药途径、分销管道、地区、细分市场预测），2025 年至 2030 年

Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Drug Class (Second- generation Antipsychotics, Third-Generation Antipsychotics), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

思觉失调症药物市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，全球思觉失调症药物市场预计到 2030 年将达到 112 亿美元，2025 年至 2030 年的复合年增长率为 5.6%。

预计思觉失调症市场将受到药物传输技术的改进、长效注射剂 (LAI) 的可用性、寻求治疗的患者数量的增加等因素的全面推动。推动新药采用的关键特征被认为是起效快、患者易于获得、效率高和患者依从性高。

思觉失调症对患者、患者家属乃至整个社会带来了沉重的负担。患者和医生对精神疾病（尤其是思觉失调症）的认识不断提高，可能会推动新药的市场渗透。目前，第二代和第三代抗精神病药物占据了很大的市场占有率。临床试验中的在研药物旨在透过阻断特定亚型的血清素和/或多巴胺受体来减轻症状、调节升高的多巴胺水平，甚至改善记忆力。

虽然预计思觉失调症市场的成长将主要由后期研发线产品的涌现推动，例如Intra-Cellular Therapies的ITI-007和Alkermes的ALKS-3831，这些产品旨在治疗阴性症状，但思觉失调症治疗领域仍存在大量未满足的需求。然而，由于对确切疾病机制的理解不足，阻碍了突破性疗法的发现，思觉失调症治疗领域仍存在大量未满足的需求。因此，需要药物传递技术的创新来治疗这种令人衰弱的疾病。

思觉失调症药物市场报告重点

  • 2024 年，第二代抗精神病药物占据最大的市场收入份额，为 73.05%。与第一代抗精神病药物相比，第二代抗精神病药物的安全性和有效性有所提高，因此思觉失调症治疗市场对第二代抗精神病药物的需求正在增加。
  • 2024年，注射型抗精神病药物治疗领域占据了最大的市场收入份额。由于注射型抗精神病药物能够应对与疾病相关的许多挑战，其需求正在不断增长。注射剂，尤其是长效注射剂 (LAI)，能够持续释放药物，有助于维持治疗水平，并降低因漏服而导致復发的风险，而漏服是口服药物常见的问题。
  • 2024 年，医院药局部门占据了最大的市场收入份额。医院药局能够提供全面的护理，包括管理复杂的用药方案和监测副作用。
  • 2024 年，北美思觉失调症药物市场占最大市场收入份额，为 38.65%。这归因于人们对思觉失调症及相关精神障碍的认识和诊断率的提高。

目录

第一章调查方法与范围

第二章执行摘要

第三章。思觉失调症药物市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 思觉失调症药物市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • 定价分析
    • 管道分析

第四章思觉失调症药物市场：药物类别估计与趋势分析

  • 全球思觉失调症药物市场：药物类别仪表板
  • 全球思觉失调症药物市场：药物类别差异分析
  • 全球思觉失调症药物市场（按类别和收益）
  • 第二代抗精神病药物
  • 第三代抗精神病药物

第五章思觉失调症药物市场：给药途径评估与趋势分析

  • 全球思觉失调症药物市场：给药途径仪表板
  • 全球思觉失调症药物市场：给药途径变化分析
  • 全球思觉失调症药物市场按给药途径和收益
  • 口服抗精神病药
  • 注射抗精神病药物

第六章思觉失调症药物市场：分销管道评估与趋势分析

  • 全球思觉失调症药物市场：分销通路仪表板
  • 全球思觉失调症药物市场：分销管道变化分析
  • 全球思觉失调症管道和收益
  • 医院药房
  • 零售药局
  • 网路药局
  • 其他的

第七章思觉失调症药物市场：区域估计与趋势分析、按药物类别、按分销管道、按给药途径

  • 区域仪表板
  • 2018-2030 年市场规模、预测与趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 主要客户
    • 2024年主要企业市场占有率分析
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company/Otsuka Holdings Co., Ltd.
    • Sumitomo Pharma Co., Ltd.
    • Eli Lilly and Company
    • Alkermes
    • VANDA PHARMACEUTICALS
    • AstraZeneca
    • AbbVie Inc.
    • Pfizer Inc.
    • H. Lundbeck A/S
Product Code: GVR-2-68038-222-8

Schizophrenia Drugs Market Growth & Trends:

The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Schizophrenia Drugs Market Report Highlights:

  • The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
  • The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
  • The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
  • North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Class
    • 1.2.2. Treatment
    • 1.2.3. Treatment
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class and Route of Administration Outlook
    • 2.2.2. Distribution Channel Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Schizophrenia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Schizophrenia Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard
  • 4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Schizophrenia Drugs Market by Class, Revenue
  • 4.4. Second-Generation Antipsychotics
    • 4.4.1. Second-Generation Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1. Risperdal (Risperidone)
        • 4.4.1.1.1. Risperdal (Risperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Invega (Paliperidone)
        • 4.4.1.2.1. Invega (Paliperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Zyprexa (Olanzapine)
        • 4.4.1.3.1. Zyprexa (Olanzapine) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Geodon (Ziprasidone)
        • 4.4.1.4.1. Geodon (Ziprasidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Seroquel (Quetiapine)
        • 4.4.1.5.1. Seroquel (Quetiapine) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Latuda (Lurasidone)
        • 4.4.1.6.1. Latuda (Lurasidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.7. Aristada (Aripiprazole Lauroxil)
        • 4.4.1.7.1. Aristada (Aripiprazole Lauroxil) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Fanapt (Iloperidone)
        • 4.4.1.8.1. Fanapt (Iloperidone) market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.9. Vraylar (Cariprazine)
        • 4.4.1.9.1. Vraylar (Cariprazine) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Third-Generation Antipsychotics
    • 4.5.1. Schizophrenia Drugs market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard
  • 5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue
  • 5.4. Oral Antipsychotics
    • 5.4.1. Oral Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Injectable Antipsychotics
    • 5.5.1. Injectable Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard
  • 6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Johnson & Johnson Services, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Class benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Class benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sumitomo Pharma Co., Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Class benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Eli Lilly and Company
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Class benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Alkermes
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Class benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. VANDA PHARMACEUTICALS
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Class benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Class benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. AbbVie Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Class benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Pfizer Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Class benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. H. Lundbeck A/S
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Class benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 3 North America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 North America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 U.S. Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 U.S. Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Canada Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 Canada Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Canada Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Mexico Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Mexico Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Europe Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Europe Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Germany Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Germany Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 UK Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 UK Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 France Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Italy Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Italy Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Italy Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Spain Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Spain Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 Spain Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 China Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 China Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 China Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Japan Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Japan Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Japan Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 India Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 India Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 India Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 South Korea Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 South Korea Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 South Korea Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Latin America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Latin America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Brazil Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 MEA Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 MEA Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 MEA Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Africa Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 57 South Africa Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Africa Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 UAE Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 UAE Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 UAE Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Schizophrenia Drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug Class and Route of Administration segment snapshot
  • Fig. 10 Route of Administration segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Schizophrenia Drugs market: Drug Class Outlook and key takeaways
  • Fig. 17 Schizophrenia Drugs market: Drug Class movement analysis
  • Fig. 18 Second-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Risperdal (Risperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Invega (Paliperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Zyprexa (Olanzapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Geodon (Ziprasidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Seroquel (Quetiapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Latuda (Lurasidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Aristada (Aripiprazole Lauroxil) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Fanapt (Iloperidone) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Saphris (Asenapine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Vraylar (Cariprazine) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Third-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Abilify (Aripiprazole) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Schizophrenia Drugs market: Route of Administration Outlook and key takeaways
  • Fig. 33 Schizophrenia Drugs market: Route of Administration movement analysis
  • Fig. 34 Oral Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Injectable Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Schizophrenia Drugs market: Distribution Channel Outlook and key takeaways
  • Fig. 37 Schizophrenia Drugs market: Distribution Channel movement analysis
  • Fig. 38 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Schizophrenia Drugs market revenue, by region, 2024 & 2030, (USD Million)
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 U.S. schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Canada schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Target disease prevalence
  • Fig. 54 Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 UK schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 Germany schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 France schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 Spain schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Italy schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 Denmark schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Sweden schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Norway schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Rest of Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Target disease prevalence
  • Fig. 83 Japan schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 China schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 India schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 Australia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Thailand schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 South Korea schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Rest of Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Target disease prevalence
  • Fig. 101 Brazil schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Target disease prevalence
  • Fig. 104 Argentina schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Rest of Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Target disease prevalence
  • Fig. 109 South Africa schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Target disease prevalence
  • Fig. 112 Saudi Arabia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 UAE schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 Kuwait schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Rest of MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)